Tokyo Tape
Sign in
← Fuso Pharmaceutical Industries

Annual report

4538.TEDINET S100OL98
Period2021-04-01 → 2022-03-31
Filed2022-06-29
StandardJapan GAAP
ConsolidatedNo
Data checks13 of 13 passed
Key figures · 88
MetricValuePeriodScopeSource row
Revenue¥49.6bn2021-04-01 → 2022-03-31StandaloneNet sales
Revenue¥49.3bn2020-04-01 → 2021-03-31StandaloneNet sales
Revenue¥46.9bn2019-04-01 → 2020-03-31dStandaloneNet sales (5-year summary)
Revenue¥46.1bn2018-04-01 → 2019-03-31dStandaloneNet sales (5-year summary)
Revenue¥45.9bn2017-04-01 → 2018-03-31dStandaloneNet sales (5-year summary)
Operating income¥1.9bn2021-04-01 → 2022-03-31StandaloneOperating income
Operating income¥2.4bn2020-04-01 → 2021-03-31StandaloneOperating income
Ordinary income¥2.0bn2021-04-01 → 2022-03-31StandaloneOrdinary income
Ordinary income¥2.2bn2020-04-01 → 2021-03-31StandaloneOrdinary income
Ordinary income¥1.1bn2019-04-01 → 2020-03-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income¥1.3bn2018-04-01 → 2019-03-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income¥832m2017-04-01 → 2018-03-31dStandaloneOrdinary income loss (5-year summary)
Profit before tax¥1.9bn2021-04-01 → 2022-03-31StandaloneIncome before income taxes
Profit before tax¥2.3bn2020-04-01 → 2021-03-31StandaloneIncome before income taxes
Net income¥1.5bn2021-04-01 → 2022-03-31StandaloneProfit loss
Net income¥1.6bn2020-04-01 → 2021-03-31StandaloneProfit loss
Net income¥707m2019-04-01 → 2020-03-31dStandaloneNet income loss (5-year summary)
Net income¥894m2018-04-01 → 2019-03-31dStandaloneNet income loss (5-year summary)
Net income¥970m2017-04-01 → 2018-03-31dStandaloneNet income loss (5-year summary)
Total assets¥69.3bnat 2022-03-31StandaloneAssets
Total assets¥69.9bnat 2021-03-31StandaloneAssets
Total assets¥69.2bnat 2020-03-31dStandaloneTotal assets (5-year summary)
Total assets¥71.7bnat 2019-03-31dStandaloneTotal assets (5-year summary)
Total assets¥70.2bnat 2018-03-31dStandaloneTotal assets (5-year summary)
Total liabilities¥34.8bnat 2022-03-31StandaloneLiabilities
Total liabilities¥36.2bnat 2021-03-31StandaloneLiabilities
Net assets / equity¥34.5bnat 2022-03-31StandaloneNet assets
Net assets / equity¥33.7bnat 2021-03-31StandaloneNet assets
Net assets / equity¥32.3bnat 2020-03-31dStandaloneNet assets
Net assets / equity¥32.8bnat 2019-03-31dStandaloneNet assets (5-year summary)
Net assets / equity¥32.6bnat 2018-03-31dStandaloneNet assets (5-year summary)
Cash and deposits¥7.3bnat 2022-03-31StandaloneCash and deposits
Cash and deposits¥7.1bnat 2021-03-31StandaloneCash and deposits
Cash & equivalents¥7.3bnat 2022-03-31StandaloneCash and cash equivalents
Cash & equivalents¥7.1bnat 2021-03-31StandaloneCash and cash equivalents
Cash & equivalents¥7.3bnat 2020-03-31dStandaloneCash and cash equivalents
Cash & equivalents¥4.8bnat 2019-03-31dStandaloneCash and cash equivalents (5-year summary)
Cash & equivalents¥5.5bnat 2018-03-31dStandaloneCash and cash equivalents (5-year summary)
Operating cash flow¥3.5bn2021-04-01 → 2022-03-31StandaloneNet cash provided by used in operating activities
Operating cash flow¥3.2bn2020-04-01 → 2021-03-31StandaloneNet cash provided by used in operating activities
Operating cash flow¥5.7bn2019-04-01 → 2020-03-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow¥2.1bn2018-04-01 → 2019-03-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow¥1.4bn2017-04-01 → 2018-03-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Investing cash flow−¥1.6bn2021-04-01 → 2022-03-31StandaloneNet cash provided by used in investment activities
Investing cash flow−¥978m2020-04-01 → 2021-03-31StandaloneNet cash provided by used in investment activities
Investing cash flow−¥1.5bn2019-04-01 → 2020-03-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow−¥2.4bn2018-04-01 → 2019-03-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow−¥984m2017-04-01 → 2018-03-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Financing cash flow−¥1.7bn2021-04-01 → 2022-03-31StandaloneNet cash provided by used in financing activities
Financing cash flow−¥2.4bn2020-04-01 → 2021-03-31StandaloneNet cash provided by used in financing activities
Financing cash flow−¥1.8bn2019-04-01 → 2020-03-31dStandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow−¥313m2018-04-01 → 2019-03-31dStandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow¥69m2017-04-01 → 2018-03-31dStandaloneNet cash provided by used in financing activities (5-year summary)
EPS (basic)¥169.092021-04-01 → 2022-03-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥183.182020-04-01 → 2021-03-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥80.592019-04-01 → 2020-03-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥101.962018-04-01 → 2019-03-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥109.612017-04-01 → 2018-03-31dStandaloneBasic earnings loss per share (5-year summary)
Dividend per share¥602021-04-01 → 2022-03-31StandaloneDividend paid per share (5-year summary)
Dividend per share¥602020-04-01 → 2021-03-31StandaloneDividend paid per share (5-year summary)
Dividend per share¥602019-04-01 → 2020-03-31dStandaloneDividend paid per share (5-year summary)
Dividend per share¥802018-04-01 → 2019-03-31dStandaloneDividend paid per share (5-year summary)
Dividend per share¥802017-04-01 → 2018-03-31dStandaloneDividend paid per share (5-year summary)
Net assets per share¥3,936.7at 2022-03-31StandaloneNet assets per share (5-year summary)
Net assets per share¥3,839.54at 2021-03-31StandaloneNet assets per share (5-year summary)
Net assets per share¥3,681.46at 2020-03-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥3,742.48at 2019-03-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥3,711.54at 2018-03-31dStandaloneNet assets per share (5-year summary)
Equity ratio49.8%at 2022-03-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio48.2%at 2021-03-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio46.7%at 2020-03-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio45.8%at 2019-03-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio46.4%at 2018-03-31dStandaloneEquity to asset ratio (5-year summary)
ROE4.3%2021-04-01 → 2022-03-31StandaloneRate of return on equity (5-year summary)
ROE4.9%2020-04-01 → 2021-03-31StandaloneRate of return on equity (5-year summary)
ROE2.2%2019-04-01 → 2020-03-31dStandaloneRate of return on equity (5-year summary)
ROE2.7%2018-04-01 → 2019-03-31dStandaloneRate of return on equity (5-year summary)
ROE3.0%2017-04-01 → 2018-03-31dStandaloneRate of return on equity (5-year summary)
Shares issued9,451,169at 2022-03-31StandaloneTotal number of issued shares (5-year summary)
Shares issued9,451,169at 2021-03-31StandaloneTotal number of issued shares (5-year summary)
Shares issued9,451,169at 2020-03-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued9,451,169at 2019-03-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued9,451,169at 2018-03-31dStandaloneTotal number of issued shares (5-year summary)
Employees1,344at 2022-03-31StandaloneNumber of employees
Employees1,356at 2021-03-31StandaloneNumber of employees
Employees1,352at 2020-03-31dStandaloneNumber of employees
Employees1,347at 2019-03-31dStandaloneNumber of employees
Employees1,366at 2018-03-31dStandaloneNumber of employees

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 2
SegmentItemPeriodValue
Pharmaceutical Businessreportable segmentemployeesat 2022-03-311288 pure
Real Estate Businessreportable segmentemployeesat 2022-03-311 pure

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 1,093
ItemContextValueUnit
Net sales on medicine business rev oaPrior1YearDuration_NonConsolidatedMember49088000000JPY
Net sales on medicine business rev oaCurrentYearDuration_NonConsolidatedMember49457000000JPY
Rent income of real estate rev oaPrior1YearDuration_NonConsolidatedMember163000000JPY
Rent income of real estate rev oaCurrentYearDuration_NonConsolidatedMember175000000JPY
Net salesPrior1YearDuration_NonConsolidatedMember49251000000JPY
Net salesCurrentYearDuration_NonConsolidatedMember49632000000JPY
Cost of sales on medicine business cos exp oaPrior1YearDuration_NonConsolidatedMember35014000000JPY
Cost of sales on medicine business cos exp oaCurrentYearDuration_NonConsolidatedMember36146000000JPY
Cost of real estate rent cos exp oaPrior1YearDuration_NonConsolidatedMember127000000JPY
Cost of real estate rent cos exp oaCurrentYearDuration_NonConsolidatedMember89000000JPY
Cost of salesPrior1YearDuration_NonConsolidatedMember35142000000JPY
Cost of salesCurrentYearDuration_NonConsolidatedMember36235000000JPY
Gross profitPrior1YearDuration_NonConsolidatedMember14109000000JPY
Gross profitCurrentYearDuration_NonConsolidatedMember13397000000JPY
Reversal of provision for sales returns gpPrior1YearDuration_NonConsolidatedMember2000000JPY
Reversal of provision for sales returns gpCurrentYearDuration_NonConsolidatedMember－JPY
Gross profit net gpPrior1YearDuration_NonConsolidatedMember14112000000JPY
Gross profit net gpCurrentYearDuration_NonConsolidatedMember13397000000JPY
Selling general and administrative expensesPrior1YearDuration_NonConsolidatedMember11760000000JPY
Selling general and administrative expensesCurrentYearDuration_NonConsolidatedMember11473000000JPY
Operating incomePrior1YearDuration_NonConsolidatedMember2351000000JPY
Operating incomeCurrentYearDuration_NonConsolidatedMember1924000000JPY
Interest and dividends income noiPrior1YearDuration_NonConsolidatedMember79000000JPY
Interest and dividends income noiCurrentYearDuration_NonConsolidatedMember82000000JPY
Insurance income noiPrior1YearDuration_NonConsolidatedMember87000000JPY
Insurance income noiCurrentYearDuration_NonConsolidatedMember152000000JPY
Gain on investments in partnership noiPrior1YearDuration_NonConsolidatedMember－JPY
Gain on investments in partnership noiCurrentYearDuration_NonConsolidatedMember67000000JPY
Other noiPrior1YearDuration_NonConsolidatedMember46000000JPY
Other noiCurrentYearDuration_NonConsolidatedMember75000000JPY
Non operating incomePrior1YearDuration_NonConsolidatedMember213000000JPY
Non operating incomeCurrentYearDuration_NonConsolidatedMember376000000JPY
Interest expenses noePrior1YearDuration_NonConsolidatedMember196000000JPY
Interest expenses noeCurrentYearDuration_NonConsolidatedMember176000000JPY
Life insurance experses noePrior1YearDuration_NonConsolidatedMember97000000JPY
Life insurance experses noeCurrentYearDuration_NonConsolidatedMember99000000JPY
Other noePrior1YearDuration_NonConsolidatedMember42000000JPY
Other noeCurrentYearDuration_NonConsolidatedMember28000000JPY
Non operating expensesPrior1YearDuration_NonConsolidatedMember336000000JPY
Non operating expensesCurrentYearDuration_NonConsolidatedMember304000000JPY
Ordinary incomePrior1YearDuration_NonConsolidatedMember2227000000JPY
Ordinary incomeCurrentYearDuration_NonConsolidatedMember1996000000JPY
Gain on sales of noncurrent assets eiPrior1YearDuration_NonConsolidatedMember91000000JPY
Gain on sales of noncurrent assets eiCurrentYearDuration_NonConsolidatedMember－JPY
Gain on sales of investment securities eiPrior1YearDuration_NonConsolidatedMember38000000JPY
Gain on sales of investment securities eiCurrentYearDuration_NonConsolidatedMember－JPY
Extraordinary incomePrior1YearDuration_NonConsolidatedMember129000000JPY
Extraordinary incomeCurrentYearDuration_NonConsolidatedMember－JPY
Loss on retirement of noncurrent assets elPrior1YearDuration_NonConsolidatedMember11000000JPY
Loss on retirement of noncurrent assets elCurrentYearDuration_NonConsolidatedMember15000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 13 of 13 passed
balance sheet identitynon_consolidated 2021-03-31pass
balance sheet identitynon_consolidated 2022-03-31pass
dei present pass
period resolution pass
statement vs summary · net assetsnon_consolidated 2020-03-31pass
statement vs summary · net assetsnon_consolidated 2021-03-31pass
statement vs summary · net assetsnon_consolidated 2022-03-31pass
statement vs summary · operating cash flownon_consolidated 2020-04-01/2021-03-31pass
statement vs summary · operating cash flownon_consolidated 2021-04-01/2022-03-31pass
statement vs summary · revenuenon_consolidated 2020-04-01/2021-03-31pass
statement vs summary · revenuenon_consolidated 2021-04-01/2022-03-31pass
statement vs summary · total assetsnon_consolidated 2021-03-31pass
statement vs summary · total assetsnon_consolidated 2022-03-31pass